Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized double-blind, double dummy, placebo and lorazepam-controlled, 4-way cross-over study to evaluate the pharmacodynamics of single oral doses of BNC210 in healthy young male subjects.

Next Previous
Trial Profile

A randomized double-blind, double dummy, placebo and lorazepam-controlled, 4-way cross-over study to evaluate the pharmacodynamics of single oral doses of BNC210 in healthy young male subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNC 210 (Primary) ; Lorazepam
  • Indications Anxiety disorders; Panic symptoms
  • Focus Pharmacodynamics

    • Most Recent Events

    • 01 Sep 2011 Results reported in a Bionomics media release, and to be presented at the European College of Neuropsychopharmacology (ECNP).
    • 30 Mar 2011 Positive results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.
    • 30 Mar 2011 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top